Get the Stockscreener App
1.67
3.09%
0.05
Pre-market:
1.67
Humacyte Inc stock is traded at $1.67, with a volume of 3.24M.
It is up +3.09% in the last 24 hours and down -4.02% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.62
Open:
$1.65
24h Volume:
3.24M
Relative Volume:
0.59
Market Cap:
$265.25M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.5607
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-2.34%
1M Performance:
-4.02%
6M Performance:
+15.17%
1Y Performance:
-66.93%
1-Day Range:
$1.60
$1.67
1-Week Range:
$1.60
$1.78
52-Week Range:
$1.15
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.67 | 303.38M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Is Humacyte Inc. stock supported by strong cash flowsPortfolio Value Summary & Short-Term Swing Trade Alerts - newser.com
Can Humacyte Inc. stock reach $100 price targetWeekly Profit Analysis & Free High Accuracy Swing Entry Alerts - newser.com
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL.com
Is Humacyte Inc. stock trading near support levels2025 Market Outlook & Low Risk Profit Maximizing Plans - newser.com
Technical analysis overview for Humacyte Inc. Equity Warrant stockCPI Data & Advanced Technical Analysis Signals - newser.com
Using data models to predict Humacyte Inc. Equity Warrant stock movementEntry Point & Free Verified High Yield Trade Plans - newser.com
Predicting Humacyte Inc. trend using moving averages2025 Investor Takeaways & Daily Technical Stock Forecast Reports - newser.com
Multi asset correlation models including Humacyte Inc. Equity Warrant2025 Fundamental Recap & Community Driven Trade Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock vulnerable to regulatory risksWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025Earnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com
Key metrics from Humacyte Inc.’s quarterly dataShare Buyback & Daily Volume Surge Trade Alerts - newser.com
Chart overlay techniques for tracking Humacyte Inc.July 2025 Snapshot & Community Verified Trade Alerts - newser.com
What recovery options are there for Humacyte Inc. Equity Warrant2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Risk Managed Investment Strategies - newser.com
Tick level data insight on Humacyte Inc. volatilityPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Is Humacyte Inc. Equity Warrant stock a dividend growth opportunityJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
Earnings visualization tools for Humacyte Inc.July 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Humacyte rises on Symvess sale to military treatment facility - MSN
Why Humacyte Inc. stock remains on buy listsMarket Trend Summary & High Accuracy Swing Trade Signals - newser.com
Why Humacyte Inc. Equity Warrant stock could outperform in 2025July 2025 Macro Moves & Community Verified Swing Trade Signals - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buying2025 Earnings Impact & Fast Moving Trade Plans - newser.com
Historical volatility pattern of Humacyte Inc. Equity Warrant visualized2025 Buyback Activity & Target Return Focused Picks - newser.com
Tick level data insight on Humacyte Inc. Equity Warrant volatilityWatch List & Momentum Based Trading Ideas - newser.com
Using RSI to spot recovery in Humacyte Inc. Equity WarrantWeekly Investment Recap & Entry Point Confirmation Signals - newser.com
How Humacyte Inc. Equity Warrant stock performs in high volatility marketsPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Humacyte, Inc. (HUMA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - The Manila Times
Humacyte (NASDAQ: HUMA) says Symvess matches vein in limb trauma; 86.6% patency - Stock Titan
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):